Oral Carbapenem Wins FDA Approval for cUTIs - Top-Institutions - MDSpire

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

  • By

  • Kathryn Wighton

  • June 17, 2026

  • 2 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Mass Eye and Ear
    Mass Eye and Ear

    Boston, MA

    Key Differentiators

    • Ophthalmology

  • #2

    Mass General Brigham
    Mass General Brigham

    Boston, MA

    Key Differentiators

    • General Medicine

  • #3

    Second Xiangya Hospital of Central South University
    Second Xiangya Hospital of Central South University

    Changsha, Hunan

    Key Differentiators

    • General Medicine

  • #4

    APHP (Greater Paris University Hospitals)
    APHP (Greater Paris University Hospitals)

    Paris, Île-de-France

    Key Differentiators

    • General Medicine

Original Source(s)

Oral Carbapenem Wins FDA Approval for cUTIs

  • by Kathryn Wighton

  • June 17, 2026

Related Content

Weekly HIV Regimen Meets Phase 3 Goal

The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.

Caries May Signal Oral Antibiotic Resistance

Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.

Italian healthcare professionals' real-world experience with immunization in children of non-European origin: the Vax4globe survey